Overview

Ranolazine, Ethnicity and the Metabolic Syndrome

Status:
Unknown status
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure the effect of ranolazine on ETT (exercise treadmill test) exercise duration in four ethnic subgroups with established coronary artery disease and risk factor(s) for the metabolic syndrome: Caucasian, African American, Southeast Asian and East Indian.
Phase:
Phase 4
Details
Lead Sponsor:
Atlanta Heart Specialists, LLC
Collaborator:
Gilead Sciences
Treatments:
Ranolazine